Introduction
toxicity, open-angle glaucoma, OAG, glaucoma
OCULAR HYPERTENSION, OPEN-ANGLE GLAUCOMA, PGA, GLAUCOMA, INTRAOCULAR PRESSURE
Controlling intraocular pressure (IOP), the key modifiable risk factor of conversion of ocular hypertension (OHT) to glaucoma and progression of open-angle glaucoma (OAG), remains the cornerstone of glaucoma management [IOP is determined by aqueous humour (AH) production and AH drainage through trabecular (conventional) outflow to the episcleral veins, and uveoscleral (unconventional) outflow to the orbital venous system. Trabecular outflow is significantly influenced by the episcleral venous pressure (EVP) [Topical fixed-dose combination (FDC) formulations for lowering IOP have been increasingly used worldwide because they offer a convenient mode of administration that could potentially improve adherence, and may help to reduce toxicity related to cumulative preservative exposure if a patient is receiving more than one active topical ingredient [Rho-kinase (ROCK) signalling has been identified in the TM and is an important regulator of trabecular outflow [ROCK inhibitors are the first new class of drugs for glaucoma since the mid-1990s, and their unique mechanism of action represents an opportunity to evolve OAG/OHT treatment as a monotherapy or in combination with other drug classes with complementary mechanisms [The commercially available novel FDC of netarsudil and latanoprost, a commonly used PGA which increases uveoscleral outflow, has been developed to optimize complementary IOP-lowering mechanisms [Here, we present the first large-scale randomized prospective investigation of the efficacy and safety of netarsudil/latanoprost 0.02%/0.005% (NET/LAT; Roclanda